{"title":"Preparation of a highly specific and sensitive monoclonal antibody against tilmicosin and its application in lateral flow immunoassay","authors":"Youyi Wang, Qingyue Li, Guanghua Liang, Huayun Li, Zizhe Li, Tian Gao, Lianjun Song, Xianqing Huang, Dapeng Peng, Xiya Zhang","doi":"10.1186/s44280-023-00032-w","DOIUrl":"https://doi.org/10.1186/s44280-023-00032-w","url":null,"abstract":"","PeriodicalId":74344,"journal":{"name":"One health advances","volume":" 44","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139142362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-20DOI: 10.1186/s44280-023-00033-9
Yiming Li, Yuying Yang, Yifei Wang, Timothy R. Walsh, Shaolin Wang, Chang Cai
{"title":"Molecular characterization of blaNDM-harboring plasmids reveal its rapid adaptation and evolution in the Enterobacteriaceae","authors":"Yiming Li, Yuying Yang, Yifei Wang, Timothy R. Walsh, Shaolin Wang, Chang Cai","doi":"10.1186/s44280-023-00033-9","DOIUrl":"https://doi.org/10.1186/s44280-023-00033-9","url":null,"abstract":"","PeriodicalId":74344,"journal":{"name":"One health advances","volume":"43 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138957411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Current status and trends in antimicrobial use in food animals in China, 2018–2020","authors":"Qi Zhao, Zinan Jiang, Ting Li, Min Cheng, Hongyang Sun, Mingquan Cui, Chunping Zhang, Shixin Xu, Hejia Wang, Congming Wu","doi":"10.1186/s44280-023-00029-5","DOIUrl":"https://doi.org/10.1186/s44280-023-00029-5","url":null,"abstract":"","PeriodicalId":74344,"journal":{"name":"One health advances","volume":" 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138618995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-06DOI: 10.1186/s44280-023-00024-w
Andrea T. Feßler, Yang Wang, Claire R. Burbick, Dubraska Diaz-Campos, Virginia R. Fajt, Sara D. Lawhon, Xian-Zhi Li, Brian V. Lubbers, Kelli Maddock, Ron A. Miller, Mark G. Papich, Shabbir Simjee, Michael T. Sweeney, Jeffrey L. Watts, Congming Wu, Jianzhong Shen, Stefan Schwarz
Abstract The performance of antimicrobial susceptibility testing (AST) of bacteria and the interpretation of AST results for bacteria isolated from animals are complex tasks which must be performed using standard published methodology and overseen by experts in clinical microbiology and in consultation with clinical pharmacologists. Otherwise, AST has significant potential for errors and mistakes. In this review, we provide guidance on how to correctly perform AST of bacteria isolated from animals and interpret the AST results. Particular emphasis is placed on the various approved or published methodologies for the different bacteria as well as the application of interpretive criteria, including clinical breakpoints and epidemiological cut-off values (ECVs/ECOFFs). Application of approved interpretive criteria and definitions of susceptible, susceptible dose-dependent, nonsusceptible, intermediate, and resistant for clinical breakpoints as well as wild-type and non-wildtype for ECVs, are explained and the difficulties resulting from the lack of approved clinical breakpoints for other bacteria, indications, and animal species is discussed. The requirement of quality controls in any AST approach is also emphasized. In addition, important parameters, often used in monitoring and surveillance studies, such as MIC 50 , MIC 90 , and testing range, are explained and criteria for the classification of bacteria as multidrug-resistant, extensively drug-resistant or pandrug-resistant are provided. Common mistakes are presented and the means to avoid them are described. To provide the most accurate AST, one must strictly adhere to approved standards or validated methodologies, like those of the Clinical and Laboratory Standards Institute or other internationally accepted AST documents and the detailed information provided therein.
{"title":"Antimicrobial susceptibility testing in veterinary medicine: performance, interpretation of results, best practices and pitfalls","authors":"Andrea T. Feßler, Yang Wang, Claire R. Burbick, Dubraska Diaz-Campos, Virginia R. Fajt, Sara D. Lawhon, Xian-Zhi Li, Brian V. Lubbers, Kelli Maddock, Ron A. Miller, Mark G. Papich, Shabbir Simjee, Michael T. Sweeney, Jeffrey L. Watts, Congming Wu, Jianzhong Shen, Stefan Schwarz","doi":"10.1186/s44280-023-00024-w","DOIUrl":"https://doi.org/10.1186/s44280-023-00024-w","url":null,"abstract":"Abstract The performance of antimicrobial susceptibility testing (AST) of bacteria and the interpretation of AST results for bacteria isolated from animals are complex tasks which must be performed using standard published methodology and overseen by experts in clinical microbiology and in consultation with clinical pharmacologists. Otherwise, AST has significant potential for errors and mistakes. In this review, we provide guidance on how to correctly perform AST of bacteria isolated from animals and interpret the AST results. Particular emphasis is placed on the various approved or published methodologies for the different bacteria as well as the application of interpretive criteria, including clinical breakpoints and epidemiological cut-off values (ECVs/ECOFFs). Application of approved interpretive criteria and definitions of susceptible, susceptible dose-dependent, nonsusceptible, intermediate, and resistant for clinical breakpoints as well as wild-type and non-wildtype for ECVs, are explained and the difficulties resulting from the lack of approved clinical breakpoints for other bacteria, indications, and animal species is discussed. The requirement of quality controls in any AST approach is also emphasized. In addition, important parameters, often used in monitoring and surveillance studies, such as MIC 50 , MIC 90 , and testing range, are explained and criteria for the classification of bacteria as multidrug-resistant, extensively drug-resistant or pandrug-resistant are provided. Common mistakes are presented and the means to avoid them are described. To provide the most accurate AST, one must strictly adhere to approved standards or validated methodologies, like those of the Clinical and Laboratory Standards Institute or other internationally accepted AST documents and the detailed information provided therein.","PeriodicalId":74344,"journal":{"name":"One health advances","volume":"63 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135634803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-13DOI: 10.1186/s44280-023-00026-8
Can Kong, Dan Li, Yanxin Hu, Peng Gao, Yongning Zhang, Lei Zhou, Xinna Ge, Xin Guo, Jun Han, Hanchun Yang
Abstract The genome segment for replicase protein nsp2 represents the fastest evolving region of porcine reproductive and respiratory syndrome virus (PRRSV), and our previous studies have shown that the PRRSV nsp2 genetic variation contributes to poor cross-neutralization. By using in vitro antibody absorption assay, here we show that the papain-like protease 2 (PLP2) domain of nsp2 is a target of neutralizing antibodies. This was further verified by cross-neutralization assay with a series of inter-lineage chimeric mutants between the Chinese highly pathogenic PRRSV (HP-PRRSV) strain JXwn06 and the low virulent NADC30-like strain CHsx1401 (lineage 1). The role of nsp2 in protective immunity was subsequently tested in a one-month SPF piglet model by immunizing the piglets with CHsx1401 or its derivatives carrying JXwn06 structural protein region (SP) alone (CHsx1401-SP JX ) or in combination with PLP2 region (CHsx1401-SPplp2 JX ), or the whole nsp2 region (CHsx1401-SPnsp2 JX ), followed by challenge with JXwn06 at 42 days post immunization, a time point when the viremia was undetectable. All chimera groups were protected from the challenge by JXwn06, whereas the group CHsx1401 failed to provide beneficial protection. Interestingly, the group CHsx1401-SPnsp2 JX , but not CHsx1401-SPplp2 JX , showed the lowest lung microscopic lesions and viral tissue load. Significantly, the vaccine virus CHsx1401-SPnsp2 JX was undetectable in the examined tissues, and so was for the challenge virus except for one piglet, highlighting an important role of HP-PRRSV nsp2 in promoting viral clearance. The findings provide insight into the mechanisms underlying the protective immunity against PRRSV and have important implications in PRRSV vaccine development.
{"title":"The replicase protein nsp2 of Chinese highly pathogenic porcine reproductive and respiratory virus is involved in protective immunity by promoting viral clearance","authors":"Can Kong, Dan Li, Yanxin Hu, Peng Gao, Yongning Zhang, Lei Zhou, Xinna Ge, Xin Guo, Jun Han, Hanchun Yang","doi":"10.1186/s44280-023-00026-8","DOIUrl":"https://doi.org/10.1186/s44280-023-00026-8","url":null,"abstract":"Abstract The genome segment for replicase protein nsp2 represents the fastest evolving region of porcine reproductive and respiratory syndrome virus (PRRSV), and our previous studies have shown that the PRRSV nsp2 genetic variation contributes to poor cross-neutralization. By using in vitro antibody absorption assay, here we show that the papain-like protease 2 (PLP2) domain of nsp2 is a target of neutralizing antibodies. This was further verified by cross-neutralization assay with a series of inter-lineage chimeric mutants between the Chinese highly pathogenic PRRSV (HP-PRRSV) strain JXwn06 and the low virulent NADC30-like strain CHsx1401 (lineage 1). The role of nsp2 in protective immunity was subsequently tested in a one-month SPF piglet model by immunizing the piglets with CHsx1401 or its derivatives carrying JXwn06 structural protein region (SP) alone (CHsx1401-SP JX ) or in combination with PLP2 region (CHsx1401-SPplp2 JX ), or the whole nsp2 region (CHsx1401-SPnsp2 JX ), followed by challenge with JXwn06 at 42 days post immunization, a time point when the viremia was undetectable. All chimera groups were protected from the challenge by JXwn06, whereas the group CHsx1401 failed to provide beneficial protection. Interestingly, the group CHsx1401-SPnsp2 JX , but not CHsx1401-SPplp2 JX , showed the lowest lung microscopic lesions and viral tissue load. Significantly, the vaccine virus CHsx1401-SPnsp2 JX was undetectable in the examined tissues, and so was for the challenge virus except for one piglet, highlighting an important role of HP-PRRSV nsp2 in promoting viral clearance. The findings provide insight into the mechanisms underlying the protective immunity against PRRSV and have important implications in PRRSV vaccine development.","PeriodicalId":74344,"journal":{"name":"One health advances","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135853653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-28DOI: 10.1186/s44280-023-00023-x
Yuanyuan Chen, Honglin Liu, Tianhui An, Qian Wu, Hongtao Zhang, Juan J. Loor, Jiaxin Cheng, Junqi Wang, Jian Sun
Abstract Aflatoxin B1 (AFB1) is a widely spread mycotoxin that poses a threat to the healthy to human and animals. The liver is the main target organ for AFB1-induced damage, primarily causing inflammatory injury and oxidative stress. When AFB1 enters the body, it can damage the intestinal barrier function, and its metabolites are transported to the liver. Therefore, the damage to the liver is closely associated with intestinal barrier impairment. Lactobacillus plays a crucial role in mitigating liver damage by improving the intestinal barrier function. In our previous report, we reported that Lactobacillus reduces liver damage caused by AFB1. However, it is still unclear how the intestinal barrier contributes to the protective effects of Lactobacillus against AFB1. To investigate the protective effects and intestinal barrier mechanisms of Lactobacillus intestinals /rhamnosus against AFB1-induced liver damage, we orally administered AFB1 and Lactobacillus intestinals/rhamnosus to male SD rats. Then the body weight, organ index, histopathological changes in the liver and gut, liver and kidney function indicators, intestinal mucosal barrier indicators, serum AFB1 content and inflammatory factors, liver oxidative stress index, and short-chain fatty acids content were analyzed. Our findings demonstrate that exposure to AFB1 resulted in changes in liver histopathology and biochemical functions, altered inflammatory response and oxidative stress, compromised the intestinal mucosal barrier, and induced the accumulation of inflammatory factor and inflammation in the liver. However, supplementation with Lactobacillus intestinals or Lactobacillus rhamnosus significantly prevented AFB1-induced liver injury, alleviated histopathological changes and hepatic injury by the maintenance of intestinal mucosal barrier integrity.
{"title":"Lactobacillus intestinalis/Lactobacillus rhamnosus protects against AFB1-induced liver damage: involvement of intestinal mucosal barrier","authors":"Yuanyuan Chen, Honglin Liu, Tianhui An, Qian Wu, Hongtao Zhang, Juan J. Loor, Jiaxin Cheng, Junqi Wang, Jian Sun","doi":"10.1186/s44280-023-00023-x","DOIUrl":"https://doi.org/10.1186/s44280-023-00023-x","url":null,"abstract":"Abstract Aflatoxin B1 (AFB1) is a widely spread mycotoxin that poses a threat to the healthy to human and animals. The liver is the main target organ for AFB1-induced damage, primarily causing inflammatory injury and oxidative stress. When AFB1 enters the body, it can damage the intestinal barrier function, and its metabolites are transported to the liver. Therefore, the damage to the liver is closely associated with intestinal barrier impairment. Lactobacillus plays a crucial role in mitigating liver damage by improving the intestinal barrier function. In our previous report, we reported that Lactobacillus reduces liver damage caused by AFB1. However, it is still unclear how the intestinal barrier contributes to the protective effects of Lactobacillus against AFB1. To investigate the protective effects and intestinal barrier mechanisms of Lactobacillus intestinals /rhamnosus against AFB1-induced liver damage, we orally administered AFB1 and Lactobacillus intestinals/rhamnosus to male SD rats. Then the body weight, organ index, histopathological changes in the liver and gut, liver and kidney function indicators, intestinal mucosal barrier indicators, serum AFB1 content and inflammatory factors, liver oxidative stress index, and short-chain fatty acids content were analyzed. Our findings demonstrate that exposure to AFB1 resulted in changes in liver histopathology and biochemical functions, altered inflammatory response and oxidative stress, compromised the intestinal mucosal barrier, and induced the accumulation of inflammatory factor and inflammation in the liver. However, supplementation with Lactobacillus intestinals or Lactobacillus rhamnosus significantly prevented AFB1-induced liver injury, alleviated histopathological changes and hepatic injury by the maintenance of intestinal mucosal barrier integrity.","PeriodicalId":74344,"journal":{"name":"One health advances","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135386461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：